KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Receivables (2016 - 2025)

Quest Diagnostics' Receivables history spans 17 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Receivables rose 7.98% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 7.98%, while the annual FY2025 figure was $1.4 billion, 7.98% up from the prior year.
  • Receivables for Q4 2025 was $1.4 billion at Quest Diagnostics, down from $1.5 billion in the prior quarter.
  • Across five years, Receivables topped out at $1.5 billion in Q3 2021 and bottomed at $1.2 billion in Q4 2022.
  • The 5-year median for Receivables is $1.3 billion (2024), against an average of $1.3 billion.
  • The largest annual shift saw Receivables surged 41.97% in 2021 before it fell 16.9% in 2022.
  • A 5-year view of Receivables shows it stood at $1.4 billion in 2021, then fell by 16.9% to $1.2 billion in 2022, then rose by 1.26% to $1.2 billion in 2023, then increased by 7.77% to $1.3 billion in 2024, then increased by 7.98% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for DGX's Receivables are $1.4 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025).